StockUS listing USLVCLFPINKHealthcareCapital Destroyer

Living Cell Technologies Limited(LVCLF) Stock Analysis | Healthcare

USD --+0.00%
Reward29Low
Risk25Low
75%Data
Revenue growing 13% YoY
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 20.56M
Reward Ratingⓘ29 Low reward assessment · 75% data coverage
Bottom 1% of stocksView factors
Risk Ratingⓘ25 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on LVCLF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Living Cell Technologies Limited?

Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand.

AI Brief Pro

The brief on Living Cell Technologies Limited

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Living Cell Technologies Limited?

Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient for the treatment of cardiovascular disease, such as hypertension; and NTCELL, an alginate coated capsule product for the treatment of Parkinson's disease. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 20.56M.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (29)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.177
Insider Activity
12M windowNo data
No insider activity data available for this ticker.